Abstract Number: 2189 • ACR Convergence 2022
Impact of a Fatigue and Energy Management Program for Persons with Systemic Sclerosis (FAME-iSS): A Pilot Study
Background/Purpose: Fatigue is one of the most prevalent and disabling symptom reported by people with systemic sclerosis (SSc). No fatigue-specific programs exist for people with…Abstract Number: 1049 • ACR Convergence 2022
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). A new definition for precapillary PH is proposed. Risk stratification is…Abstract Number: 1178 • ACR Convergence 2022
Key Features of Human Fibrosing Interstitial Lung Disease Are Captured in a Preclinical Mouse Model upon Repetitive, but Not Single Intratracheal Bleomycin Dosing
Background/Purpose: Repetitive alveolar epithelial injury together with dysregulated tissue repair is crucial for the transition of acute self-limiting to chronic-persisting inflammation and fibrosis in fibrosing…Abstract Number: 1524 • ACR Convergence 2022
Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of scleroderma-related mortality. This work identifies factors associated with SSc-ILD decline on pulmonary function…Abstract Number: 1731 • ACR Convergence 2022
Systemic Sclerosis-Associated Class II HLA Alleles Restrict the Diversity of the CDR3 and the T Cell Receptor Repertoire in African American Patients
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune, fibrotic disorder that disproportionately affects African Americans (AA). Previous work from our lab and others has suggested a…Abstract Number: 2190 • ACR Convergence 2022
Characterizing Compensatory Cognitive Strategy Use in People with Systemic Sclerosis
Background/Purpose: Individuals with systemic sclerosis (SSc) report cognitive problems that worsen symptoms and daily activity performance. Compensatory cognitive strategies (CCS) are commonly taught to help…Abstract Number: 1050 • ACR Convergence 2022
Clinically Recognized Depression and Mental Health Treatment in a Single Center Cohort of Patients with Systemic Sclerosis
Background/Purpose: The prevalence of depression among patients with systemic sclerosis (SSc) is 35-65%1, yet little is known about mental health care utilization in SSc. It…Abstract Number: 1179 • ACR Convergence 2022
Single Cell RNA Sequencing Analysis of Cryopreserved versus Fresh Skin Biopsy Samples from Systemic Sclerosis Patients and Healthy Controls
Background/Purpose: Single cell RNA Sequencing (scRNA-Seq) can elucidate tissue-resident cell populations and gene expression profiles with unprecedented granularity. Application of this approach to systemic sclerosis…Abstract Number: 1526 • ACR Convergence 2022
Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score
Background/Purpose: High resolution computed tomography (HRCT) is the gold standard for the diagnosis of systemic sclerosis associated interstitial lung disease (SSc-ILD). Although there is agreement…Abstract Number: 1874 • ACR Convergence 2022
Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease
Background/Purpose: In some patients, interstitial lung disease (ILD) may be the dominant or even sole overt manifestation of an otherwise unrecognised autoimmune connective tissue disease…Abstract Number: 0403 • ACR Convergence 2021
Effect of Nintedanib on KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
Background/Purpose: Krebs von den Lungen-6 (KL-6), a marker of lung epithelial and endothelial injury, has been associated with progression of interstitial lung disease associated with…Abstract Number: 0550 • ACR Convergence 2021
Treatment Regimens and Outcomes in Systemic Sclerosis-associated Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). It is associated with impaired quality of life and high mortality.…Abstract Number: 1047 • ACR Convergence 2021
Exposure to Industrial Pollutants and Mortality Due to Inmune-mediated Inflammatory Systemic Diseases (IMD) in Spain
Background/Purpose: The etiology of many IMD is largely unknown; however, available data suggest that environmental contaminants could play a role in their origin. Industrial facilities…Abstract Number: 1382 • ACR Convergence 2021
Survey on Treatment Practices in Subclinical Interstitial Lung Disease in Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc). Early detection and treatment of SSc-ILD may lead to improved…Abstract Number: 1840 • ACR Convergence 2021
Can Dual-energy CT Lung Perfusion Detect Abnormalities at the Level of Lung Circulation in Systemic Sclerosis (SSc) ? Preliminary Experience in 101 Patients
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder that is characterized by a interplay of vascular abnormalities, immune system activation and an uncontrolled fibrotic response…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 46
- Next Page »